Polycythemia Vera
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, the level of RUNX1/AML1 and NF-E2 transcripts that are specifically upregulated in acquired polycythemia vera were also upregulated in VHL(P138L) granulocytes.
|
23538339 |
2013 |
Polycythemia Vera
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
One Sp1 target, the transcription factor NF-E2 [nuclear factor (erythroid-derived 2)], is overexpressed 2- to 40-fold in PV patients.
|
15801966 |
2005 |
Polycythemia Vera
|
0.070 |
Biomarker
|
disease |
BEFREE |
Overexpression of transcription factors runt-related transcription factor 1 (RUNX1) and nuclear factor, erythroid-derived 2 (NF-E2) was reported in granulocytes of patients with polycythemia vera and other myeloproliferative neoplasms (MPNs).
|
24297870 |
2014 |
Polycythemia Vera
|
0.070 |
Biomarker
|
disease |
BEFREE |
Silencing NF-E2 in PV patients reverted both aberrancies, demonstrating for the first time that NF-E2 overexpression is both required and sufficient for Epo independence and HSC/CMP expansion in PV.
|
23341442 |
2013 |
Polycythemia Vera
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Patients with PV who were homozygous or heterozygous for JAK2-V617F exhibited higher levels of expression of the 13 new markers, PRV1, and NF-E2 than patients without JAK2-V617F, whereas ANKRD15 was down-regulated in these patients.
|
16081684 |
2005 |
Polycythemia Vera
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
They include one patient with PV and +9p with three copies of JAK2 and two patients with MDS and JAK2 relocations: one with NF-E2, while the other patient with a TEL/ETV6 rearrangements also had tetrasomy for JAK2.
|
17976519 |
2007 |
Polycythemia Vera
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Although NF-E2 levels correlate with JAK2(V671F) allele burden in some PV cohorts, the molecular mechanism causing aberrant NF-E2 expression has not been described.
|
20339092 |
2010 |
Chronic myeloproliferative disorder
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
In murine models, elevated NFE2 levels cause an MPN phenotype with spontaneous leukemic transformation.
|
29519804 |
2018 |
Chronic myeloproliferative disorder
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
We report that RUNX1 and NF-E2 overexpression is not specific for MPN; these transcripts were also significantly elevated in polycythemias with augmented hypoxia-inducible factor activity whose erythroid progenitors were hypersensitive to EPO.
|
24297870 |
2014 |
Chronic myeloproliferative disorder
|
0.070 |
Biomarker
|
disease |
BEFREE |
These data establish a role for NF-E2 in the pathophysiology of MPNs and provide a molecular rationale for investigating epigenetic alterations as novel targets for rationally designed MPN therapies.
|
22231305 |
2012 |
Chronic myeloproliferative disorder
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Our data underscore the role of increased NF-E2 activity in the pathophysiology of MPNs.
|
23589569 |
2013 |
Chronic myeloproliferative disorder
|
0.070 |
Biomarker
|
disease |
BEFREE |
Results of NFE2 and calreticulin immunohistochemistry of MPN TMAs are consistent with previously published data.
|
27544663 |
2017 |
Chronic myeloproliferative disorder
|
0.070 |
Biomarker
|
disease |
BEFREE |
Modulation by GVS of NFE2 was also observed in freshly isolated CD34(+) cells from MPN patients, and was accompanied by inhibition of their proliferation and differentiation toward the erythroid lineage.
|
22579713 |
2012 |
Chronic myeloproliferative disorder
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Our data identify NF-E2 as a novel AML1 target gene and delineate a role for aberrant AML1 expression in mediating elevated NF-E2 expression in MPN patients.
|
20339092 |
2010 |
Acute Erythroblastic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Retroviral insertional activation of Fli-1 and Spi-1/PU.1, as well as loss of tumour suppressor genes such as p53 or p45 NFE2 have been shown to be critical for the induction and progression of Friend virus-induced erythroleukemias.
|
12894591 |
2003 |
Acute Erythroblastic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Using a chromatin immunoprecipitation assay, we provide evidence for NF-E2 binding directly and specifically to HS2 in living erythroleukemia cells and in mouse fetal liver.
|
10891470 |
2000 |
Acute Erythroblastic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
This site is occupied by transcription factors USF1, USF2, EGR1, MafK, and NF-E2 in the human erythroleukemia cell line K562 and exhibits histone modifications typical for enhancers.
|
30012865 |
2018 |
Acute Erythroblastic Leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
JNK-mediated turnover and stabilization of the transcription factor p45/NF-E2 during differentiation of murine erythroleukemia cells.
|
19966288 |
2010 |
Acute Erythroblastic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
The mechanism of NF-E2-mediated chromatin modification was investigated by complementation analysis in NF-E2-null CB3 erythroleukemia cells.
|
14597626 |
2004 |
Acute Erythroblastic Leukemia
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
This analysis indicates that binding sites for the hematopoietic transcription factors NF-E2 and GATA-1 are required for the formation of the characteristic chromatin structure of the HS following stable transfection into murine erythroleukemia cells.
|
7828582 |
1995 |
Myeloproliferative disease
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Recently, an increased in NF-E2 activity has been implicated in myeloproliferative neoplasms.
|
28648895 |
2017 |
Myeloproliferative disease
|
0.060 |
GeneticVariation
|
group |
BEFREE |
The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
|
22579713 |
2012 |
Myeloproliferative disease
|
0.060 |
AlteredExpression
|
group |
BEFREE |
AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.
|
20339092 |
2010 |
Myeloproliferative disease
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We previously described NFE2 mutations in patients with myeloproliferative neoplasms and demonstrated that expression of mutant NFE2 in mice causes a myeloproliferative phenotype.
|
30755419 |
2019 |
Myeloproliferative disease
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms.
|
29519804 |
2018 |